NSAIDs: The Truth About Cardiovascular Risk

Transcription

1 NSAIDs: The Truth About Cardiovascular Risk Adam Grunbaum DO FACOI FACR American College of Osteopathic Internists Annual Convention and Scientific Sessions October 3 rd 2015

2 Disclosures none 2

3 Objectives Understand the risks associated with NSAID use in patients with and without history of cardiovascular disease Identify what patients are at highest risk for cardiovascular complications with NSAID use and when alternate therapies should be considered Understand factors that limit risk of cardiovascular events associated with NSAIDs 3

4 Questions 1. Do NSAIDs increase cardiovascular risk in those with and without a history of known cardiovascular disease? 2. Are there any NSAIDs that confer less risk of cardiovascular events? 3. What settings should NSAID use be considered contra-indicated from a primarily cardiovascular standpoint? 4. Are there any other settings where NSAID use should be avoided from a cardioprotective standpoint? 4

5 History of NSAIDs Aspirin has been on the market for greater than 115 years The NSAIDs class constitute a chemically heterogenous group of compounds with drug specific selectivity that provide shared therapeutic effects Analgesic Anti-inflammatory Antipyretic Marketing of NSAIDs began ~1963 with indomethacin Since then over 20 additional NSAIDs have been developed Estimated 70 million prescription NSAIDs written each year in the United States Combining over the counter use of NSAIDs 30 billion doses are consumed annually 5

6 History of NSAIDs Approximately 15 years ago selective inhibitors of cyclooxygenase-2 developed Showed promise based on anti-pyretic, anti-inflammatory and analgesics effects as a class Variability of effects noted based on pharmacokinetics and pharmacodynamics Development continued with unique targets elucidated i.e. chemoprevention of colorectal carcinoma As dosage limits pushed with newer drugs toxicity profiles became increasingly apparent Multiple NSAIDs demonstrated vascular toxicity represented by heart failure and new onset or worsening of hypertension* This culminated in newer agents suggesting increased risk of cardiovascular thrombotic effects This was a surprise as aspirin had been shown to be cardioprotective to events in doses up to 1500mg a day** *Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003; 14: **Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothromosis. NEJM 2005;353:

7 NSAIDs and Cardiovascular Risk September 2004 Merck voluntarily withdraws rofecoxib due to reports of increased heart attack and stroke December 2004 FDA announces a black box warning for valdecoxib adding a contra-indication in patients undergoing coronary artery bypass grafting surgery One week after black box warning NIH suspends use of celecoxib in the Adenoma Prevention with Celecoxib trial due to increased cardiac events Three days later NIH halts the Alzheimer's Disease Anti-inflammatory Prevention Trial as it showed an increased risk in cardiovascular events in those patients receiving naproxen in the trial but not in those given celecoxib December 23, 2004 FDA issues public health advisory for rofecoxib, valdecoxib, celecoxib and naproxen 7

8 US Food and Drug Administration Public Health Advisory December 2004 Health Advisory Physicians prescribing celecoxib or valdecoxib should consider the emerging information when weighing the benefits against risks for individual patients. Patients who are at a high risk of gastrointestinal (GI) bleeding, have a history of intolerance to nonselective NSAIDs, or are not doing well on nonselective NSAIDs may be appropriate candidates for COX-2 selective agents. Individual patient risk for cardiovascular events and other risks commonly associated with NSAIDs should be taken into account for each prescribing situation. Consumers are advised that all over-the-counter (OTC) pain medicines, including NSAIDs, should be used in strict accordance with the label directions. If use of an (OTC) NSAID is needed for longer than ten days, a physician should be consulted. April 2005 News Release FDA asks valdecoxib sales and marketing to be suspended in the US FDA requires celecoxib and all other prescription NSAIDs to have black box warning including CV events FDA urges OTC NSAIDs to have more specific warnings of CV and GI events 8

9 NSAID Cardiovascular Controversy Begins 9

10 Why are we here today??? FDA announcement July 2015 strengthens warnings for cardiovascular or cerebrovascular events Based on the advisory committees recommendations, the prescription NSAID labels were revised to reflect the following information: The risk of heart attack or stroke can occur as early as the first weeks of using an NSAID. The risk may increase with longer use of the NSAID. The risk appears greater at higher doses. It was previously thought that all NSAIDs may have a similar risk. Newer information makes it less clear that the risk for heart attack or stroke is similar for all NSAIDs; however, this newer information is not sufficient to determine that the risk of any particular NSAID is definitely higher or lower than that of any other particular NSAID. NSAIDs can increase the risk of heart attack or stroke in patients with or without heart disease or risk factors for heart disease. A large number of studies support this finding, with varying estimates of how much the risk is increased, depending on the drugs and the doses studied. In general, patients with heart disease or risk factors for it have a greater likelihood of heart attack or stroke following NSAID use than patients without these risk factors because they have a higher risk at baseline. Patients treated with NSAIDs following a first heart attack were more likely to die in the first year after the heart attack compared to patients who were not treated with NSAIDs after their first heart attack. There is an increased risk of heart failure with NSAID use. FDA Drug Safety Communication

11 NSAIDs and Cardiovascular Risk NSAIDs differ many ways Chemical class Chemical structures Variability in the manner in which they inhibit COX-1 and COX-2 isoenzymes Causes varying effect on: Antipyretic effects Analgesic effects Anti-inflammatory effects 11

12 Elliott M. Antman et al. Circulation. 2005;112: Copyright American Heart Association, Inc. All rights reserved.

13 NSAIDs and Cardiovascular Risk How do aspirin derivatives increase risk of atherothrombosis??? NSAIDs selective and/or non-selective in inhibiting cyclooxygenase What does cyclooxygenase do? COX-1: produces prostaglandins used for stimulation of typical body functions i.e. stomach mucous production, regulation of gastric acid and kidney water excretion COX-2: produces prostaglandins used for signaling pain and inflammation 13

14 NSAIDs and Cardiovascular Risk Has been proposed that the major cardiovascular complications are COX-2 inhibition mediated as blocking COX-2 shifts prothrombotic or antithrombotic balance on endothelial surfaces Loss of protective effects of COX-2 upregulation May lead to myocardial ischemia and infarction Can lead to larger infarct size, greater thinning of ventricular wall in infarct zone and increased tendency for myocardial rupture* Increases in sodium and water retention edema hypertension HF Imbalance of production of prostanoids, a subclass of eicosanoids containing: Prostaglandins mediate inflammatory and anaphylactic reactions Thromboxanes mediate vasoconstriction Prostacyclins an active part of the resolution phase of inflammation 14 *Circulation 2007;115: and

15 Prostanoid Hypothesis Clinical Medicine & Research. Volume 5, Number 1:

16 Figure 4. Consequences of COX inhibition for prostacyclin and thromboxane A2 production in normal and atherosclerotic arteries. Elliott M. Antman et al. Circulation. 2005;112: Copyright American Heart Association, Inc. All rights reserved.

17 Considerations What factors play a role in NSAIDs and potential adverse cardiovascular effects? Does dose of NSAID matter? How long can NSAIDs be used before risk unacceptable? Are there any patient types more at risk? Is risk the same for those for primary and secondary events? Which agents, if any, confer the most risk? Is there additive therapy that can diminish this risk? What evidence is out there to answer any of these questions? Most current knowledge from collections of post hoc analyses of subgroups of patients from studies designed to look at non-cardiovascular diseases Focus has primarily been on COX-2 inhibitors with nonselective NSAID risk estimated primarily from metaanalyses and observational studies 17

18 NSAIDs and Cardiovascular Risk To date there are a number of large systematic reviews published covering randomized trials and non-randomized pharmaco-epidemiological studies NSAIDs and the risk of myocardial infarction in the general population Circulation 109: Relationship between COX-2 inhibitors and myocardial infarction in older adults Circulation 109: Cardiovascular Risk and inhibition of cyclooxygenase: a systematic review of observational studies of selective and non-selective COX inhibitors JAMA 296: Do COX-2 inhibitors and traditional NSAIDs increase the risk of atherothrombosis? 2006 BMJ 332: Cardiovascular Safety of NSAIDs: network meta-analysis BMJ 342: c7086 NSAID use selectively increases risk of non-fatal myocardial infarction PLoS ONE 6: e16780 NSAIDs and the risk of myocardial infarction Basic Clin Pharmacol 98: Coxib and traditional NSAID Trialists' (CNT) Collaboration. The Lancet, Volume 382, Issue 9894, 2013, Many of these studies use the same data looking for different endpoints and to this point it is all that is available PRECISION is coming.. 18

19 Does Dose Matter??? From a heart failure and ischemic cardiovascular event standpoint there is little data available to estimate risk but in the studies available there seems to be consensus that low dose NSAIDs (especially short term) do not confer as significant a risk What is considered high dose of commonly used NSAIDs Ibuprofen > 1200mg daily Diclofenac > 100mg daily Naproxen >500mg daily Celecoxib > 200 mg daily Rofecoxib > 25mg daily (no longer on the market) 19

20 What Duration of Treatment Matters?? Very few time to event analyses are available to answer this Only a couple studies were randomized and designed specifically to look at this question but these were in the setting of the immediate post operative period with coronary artery bypass grafting (CABG) Findings here have been very consistent with COX-2 inhibitors leading to an absolute contra-indication in the immediate weeks post CABG These studies prompted some analyses of duration to treatment risk in patients with history of myocardial infarction Circulation. 2011; 123: ,677 patients 30 years old admitted for first time AMI from Used registry data from Denmark for drug dispensing registries Strength: avoided selection bias Weakness: Observational 20

21 Time-dependent Cox proportional-hazard analysis of risk of death/recurrent myocardial infarction (Re-MI) according to duration of nonsteroidal anti-inflammatory drug (NSAID) treatment in patients with prior myocardial infarction. Anne-Marie Schjerning Olsen et al. Circulation. 2011;123: Copyright American Heart Association, Inc. All rights reserved.

22 Hypertension Risks Generally well accepted that most NSAIDs carry risk of elevating blood pressure Effects seem dose-dependent and probably involves inhibition of cyclooxygenase-2 (COX-2) in the kidneys Presumably reducing sodium excretion and increasing intravascular volume Hard to generalize severity of effects on blood pressure as specific agents vary greatly on their effects Indomethacin and Naproxen most consistently seem to cause greatest increases in mean arterial pressure (~3-4 mmhg) Arch Intern Med. 1993;153(4):477. Some studies have shown potential of NSAIDs to antagonize most anti-hypertensive treatments with the exception of calcium channel blockers Hypertension. 2007;49(3):408 22

23 Heart Failure Risks Also generally well accepted as a potential risk for developing heart failure and significant risk noted in NSAID users with history of heart failure ACC guidelines discourage use of all NSAIDs in patients with chronic heart failure for some years now AHA has published prior scientific statements recommending against use of NSAIDs, particularly COX-2 inhibitors, in patients with established heart failure independent of severity of disease Arch Internal Medicine. 2009; 169(2): ,092 patients surviving initial hospitalization due to heart failure Aged 30 years or older Registry data collected from pharmacies concerning NSAID use Cox proportional hazard models adjusted for age, sex, comorbidity, medical treatment, case based severity. 23

24 From: Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure Arch Intern Med. 2009;169(2): doi: /archinternmed Figure Legend: Hazard ratios for hospitalization because of heart failure associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with chronic heart failure. Cox proportional hazards regression analysis adjusted for age, sex, calendar year, comorbidity, concomitant pharmacotherapy, and severity of disease. Bars indicate 95% confidence intervals. Copyright 2015 American Medical Association. All rights reserved.

25 From: Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure Arch Intern Med. 2009;169(2): doi: /archinternmed Figure Legend: Hazard ratios for death associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with chronic heart failure. Cox proportional hazards regression analysis adjusted for age, sex, calendar year, comorbidity, concomitant pharmacotherapy, and severity of disease. Bars indicate 95% confidence intervals. Copyright 2015 American Medical Association. All rights reserved.

26 From: Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure Arch Intern Med. 2009;169(2): doi: /archinternmed Figure Legend: Hazard ratios for hospitalization because of acute myocardial infarction associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with chronic heart failure. Cox proportional hazards regression analysis adjusted for age, sex, calendar year, comorbidity, concomitant pharmacotherapy, and severity of disease. Bars indicate 95% confidence intervals. Copyright 2015 American Medical Association. All rights reserved.

27 Cardiovascular Events: Myocardial Infarctions As the rofecoxib studies for alternative indications and doses found increasing incidence of increased ischemic CV events. Concern about celecoxib safety as only valdecoxib and rofecoxib left market Need for cardiovascular data on nonselective NSAIDs arose Concern as most countries allow non-prescription use JAMA. 2006: 296: Looked at eligible studies of case-control or cohort design on CV events Eligible studies had to report on cardiovascular risks associated with NSAID use Used nonuse/remote exposure as the reference point for risk calculation 7086 titles evaluated (from ) only 23 titles included in analysis Totaled > 86,000 events and had > 1,000,000 controls 27

28 From: Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 JAMA. 2006;296(13): doi: /jama jrv60011 Copyright 2015 American Medical Association. All rights reserved.

29 From: Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 JAMA. 2006;296(13): doi: /jama jrv60011 Copyright 2015 American Medical Association. All rights reserved.

30 From: Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 JAMA. 2006;296(13): doi: /jama jrv60011 Figure Legend: Reference exposure, nonuse or remote use of anti-inflammatory drugs (random effects model). CI indicates confidence interval. Copyright 2015 American Medical Association. All rights reserved.

31 From: Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 JAMA. 2006;296(13): doi: /jama jrv60011 Figure Legend: Reference exposure, nonuse or remote use of anti-inflammatory drugs (random effects model). CI indicates confidence interval. Copyright 2015 American Medical Association. All rights reserved.

32 Coxib and traditional NSAID Trialists' (CNT) Collaboration Lancet 2013 Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials Meta-analyses of 280 trials of NSAIDs versus placebo 124,513 participants - 68,342 person-years 474 trials of one NSAID versus another NSAID 229,296 participants person-years Main outcomes focused on major vascular events Major coronary events (non-fatal myocardial infarction or coronary death) Stroke Heart failure Upper gastrointestinal complications (perforation, obstruction, or bleed). Also looked at vascular deaths (stroke or other vascular deaths) 32

33 The Lancet, Volume 382, Issue 9894, 2013,

34 The Lancet, Volume 382, Issue 9894, 2013,

35 The Lancet, Volume 382, Issue 9894, 2013,

36 The Lancet, Volume 382, Issue 9894, 2013,

37 NSAIDs and Cardiovascular Risk Through most studies average relative risks with gastrointestinal complications are estimated around 4 but cardiovascular complications seem to center in the range of 1 to 2 Limits power of data statistically Raises importance of risk variability estimates within study participants Low vs High risk Low vs High dose Risk between similar drugs Data seem to suggest some traditional NSAIDs at higher doses seem to confer similar elevated risks to what was demonstrated with prior available COX-2 inhibitors But what about low dosing more consistently as with non-prescription use??? 37

38 Cardiovascular Risk with Non-steroidal Anti- Inflammatory Drugs: Systematic Review Based on same protocol as earlier discussed JAMA article (same authors) Confined analysis to non-randomised controlled observational designs Prior placebo controlled trial had captured insignificant events but ongoing meta-analyses and additional randomised data published now allowed for it Period reviewed this time was January 1985 to November 2010 Pair wise data was plentiful enough to be powered appropriately As many of the values of pooled relative risk found to be close to 1 a sensitivity analysis was conducted to strength of association with cardiovascular events Due to volume of analyses the sensitivity analysis was limited to pair-wise comparisons of drugs as this was most important measure of relative harm PLoS. Sept 2011; Vol 8 (9) e

39 Table 2. Dose-response relationships for individual drugs included in the analyses. McGettigan P, Henry D (2011) Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 8(9): e doi: /journal.pmed

40 Table 3. Estimated RRs of cardiovascular events according to risk of cardiovascular disease. McGettigan P, Henry D (2011) Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 8(9): e doi: /journal.pmed

41 Table 4. Selected pair-wise comparisons of individual drugs. McGettigan P, Henry D (2011) Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 8(9): e doi: /journal.pmed

42 Cardio-protection with aspirin & NSAIDs Does NSAID induced COX inhibition affect the cardio-protective effects of aspirin therapy? Quick Answer: we don t know definitively at this point (likely ibuprofen) Cardio-protective effect diminished Lancet. 2003;361: Ibuprofen shown to inhibit irreversible platelet inhibition of aspirin NEJM. 2001;345: Ibuprofen shown to affect the pharmacodynamics of aspirin but rofecoxib, acetaminophen and diclofenac did not Cardio-protective effect unaffected J Clinical Pharmacology. 2002;42: Celecoxib showed no effect on the pharmacodynamics of aspirin Circulation. 2003;108: Suggested that short term use of NSAIDs did not effect aspirin Regular use of NSAIDs (>60 days) did suggest an increased risk by loss of protective effects 42

43 Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) Patients 18 or older with a clinical diagnosis of Rheumatoid Arthritis or Osteoarthritis who require daily treatment with NSAIDs to maintain quality of life Will continue until 762 primary events are noted with at least 18 months follow-up Currently ongoing with primary endpoints of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke Secondary endpoints include first occurrence of major adverse CV event including composite of CV death (including hemorrhagic), nonfatal MI, nonfatal stroke, hospitalization for USA or TIA or revascularization. Also includes clinically significant GI events Multicenter, multinational study that is randomized, double-blind, triple dummy 3-arm parallel group design Celecoxib mg BID + Ibuprofen placebo + Naproxen placebo Ibuprofen mg TID + Celecoxib placebo + Naproxen placebo Naproxen mg BID + Celecoxib placebo + Ibuprofen placebo 43

44 Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) Key inclusion requirement is high risk for cardiovascular disease Established Disease defined as: 50% or greater occlusion of one or more coronary arteries by angiography 50% or greater occlusion of one or more carotid arteries by angiography or ultrasound History of stable angina Symptomatic peripheral arterial disease Prior: AMI, USA, PCI, CABG, TIA, Ischemic stroke, CEA or other arterial angioplasty Events must have occurred 3 months or more from randomization Diabetes Mellitus considered a cardiovascular disease equivalent Inclusion as high risk requires 3 or more atherosclerotic risk factors 44

45 Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) Major inclusion criteria Age >55 Dyslipidemia (LDL > 160 mg/dl or HDL < 40 mg/dl in females and < 35 mg/dl in males or subjects currently undergoing lipid lowering therapy with statin drugs, fibrates or niacin) Family History of premature CV disease (MI, angina pectoris, heart failure, cardiac death, or coronary revascularization, stroke, carotid endarterectomy, or other arterial surgery or angioplasty in a parent, grandparent or sibling with symptom onset before age 55 for males and 65 for females) Current smoker LVH Documented ankle brachial index < 0.9 History of microalbuminuria, urine protein-creatinine ratio >2 45

46 Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) Major exclusion criteria Unstable angina, MI, CVA, CABG <3 months from randomization Planned coronary, cerebrovascular, or peripheral revascularization Uncontrolled Hypertension (SBP >140 mmhg DBP >90 mmhg) Uncontrolled arrhythmia <3 months from randomization NYHA class III-IV heart failure or ejection fracture 35% Acute joint trauma Aspirin > 325mg daily Oral corticosteroid equivalent of prednisone > 20mg daily GI ulceration <60 days prior to randomization or GI bleed within 6 months Inflammatory bowel disease or diverticulitis active within 6 months AST, ALT or BUN >2x the upper limit of normal Creatinine level > 1.7mg/dL in men, 1.5 mg/dl in women Malignancy <5 years prior to randomization Other known, active significant GI, hepatic, renal or coagulation disorders 46

47 Summary ACC, AHA, and ACR All discourage use of all NSAIDs in patients with chronic heart failure All recommend against use of NSAIDs, particularly COX-2 inhibitors, in patients with established cardiovascular disease All recommend NSAIDs be avoided in patients taking aspirin for cardioprotective benefit If treatment becomes necessary in this patient population ibuprofen should be avoided (insufficient data to assess other NSAIDs) If the patient is at moderate to high risk of a potential cardiovascular event and treatment becomes necessary then initial management should be attempted initially with acetaminophen then naproxen 47

48 Summary Food and Drug Administration July 2015 The risk of heart attack or stroke can occur as early as the first weeks of using an NSAID. The risk appears greater at higher doses. Newer information is not sufficient to determine that the risk of any particular NSAID is definitely higher or lower than that of any other particular NSAID. NSAIDs can increase the risk of heart attack or stroke in patients with or without heart disease or risk factors for heart disease. Patients treated with NSAIDs following a first heart attack were more likely to die in the first year after the heart attack compared to patients who were not treated with NSAIDs after their first heart attack. There is an increased risk of heart failure with NSAID use. 48

49 Questions and Answers Do NSAIDs increase cardiovascular risk in those with and without a history of known cardiovascular disease? Both selective and nonselective NSAID use is associated with increased risk of cardiovascular events such as ischemic cardiovascular disease and heart failure. This effect all in drugs seems to be both dose and time dependent. Are there any NSAIDs that confer less risk of cardiovascular events? Naproxen seems through most analyses to confer the lowest risk, particularly when used for short durations, especially in those without history of cardiovascular disease What settings should NSAID use be considered contra-indicated from a primarily cardiovascular standpoint? For the treatment of peri-operative pain in the setting of coronary artery bypass grafting, recent myocardial infarction and in those patients with known heart failure Are there any other settings where NSAID use should be avoided from a cardio-protective standpoint? In patients taking low dose aspirin for cardio-protection long term NSAID use should be avoided as their use may attenuate this benefit Ibuprofen in particular should always be avoided in this setting 49